Endovia Health Sciences (EDVA) Net Income Growth (1y) (2013 - 2026)
Powered by 
Analysis
Endovia Health Sciences (EDVA) Net Income Growth (1y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.50 Bn | 133.65 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | -6.81% |
| 3 | Argenx Se | 65.05 Bn | 59.86 Bn | 1.37 Bn | 82.68% |
| 4 | Moderna | 57.11 Bn | 51.98 Bn | 52.00 Mn | 5.21% |
| 5 | Revolution Medicines | 44.71 Bn | 44.71 Bn | - | - |
| 6 | BeOne Medicines | 40.40 Bn | 35.31 Bn | 1.53 Bn | 151.28% |
| 7 | Alnylam Pharmaceuticals | 35.36 Bn | 32.05 Bn | 992.69 Mn | 327.74% |
| 8 | Royalty Pharma | 28.16 Bn | 27.32 Bn | - | -12.04% |
| 9 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 95.87% |
| 10 | Endovia Health Sciences | 801,166.21 | 558,464.21 | - | 73.10% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 73.10% |
| Mar 31, 2026 | 26.38% |
| Dec 31, 2025 | 1.51% |
| Sep 30, 2025 | -177.15% |
| Jun 30, 2025 | -96.94% |
| Mar 31, 2025 | 23.28% |
| Dec 31, 2024 | 57.51% |
| Sep 30, 2024 | 17.68% |
| Jun 30, 2024 | -2.16% |
| Mar 31, 2024 | -9.48% |
| Dec 31, 2023 | 4.42% |
| Sep 30, 2023 | 14.85% |
| Jun 30, 2023 | 25.79% |
| Mar 31, 2023 | 41.53% |
| Dec 31, 2022 | 22.40% |
| Sep 30, 2022 | 58.36% |
| Jun 30, 2022 | 14.55% |
| Mar 31, 2022 | -32.97% |
| Dec 31, 2021 | 72.61% |
| Sep 30, 2021 | -486.56% |